The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.
-
-
-
-
-
The Michael J. Fox Foundation’s development and distribution of novel alpha-synuclein viral vectors to study Parkinson's disease.
-
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits
-
The Michael J. Fox Foundation’s Efforts to Understand the Relationship between GBA1 and Alpha-Synuclein through the Development and Characterization of Preclinical Models
Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.
No results were found.
Breaking Research Updates
Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.